Moore Capital Management, LP Apellis Pharmaceuticals, Inc. Transaction History

Moore Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $3.03 Million - $4.35 Million	65,000 Added 650.0%	75,000 $4.95 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $7.35 Million - $10.4 Million	-169,958 Reduced 94.44%	10,000 $517,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $8.05 Million - $12.5 Million	179,958 New	179,958 $12.3 Million
Q2 2019 Aug 14, 2019	SELL	$18.0 - $25.34 $909,486 - $1.28 Million	-50,527 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $647,250 - $1 Million	50,527 New	50,527 $985,000

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.